FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number:	3235-0104						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

State			2. Date of Event Requiring Statement (Month/Day/Year) 06/09/2021 3. Issuer Name and Ticker or Trading Symbol Nautilus Biotechnology, Inc. [NAUT]							
(Last) C/O NAUTILUS 3 425 PONTIUS AV (Street) SEATTLE (City)	(First) BIOTECHNOLOGY ZE N, STE 202 WA (State)	(Middle) , INC.			Relationship of Reporting Person(s) to Iss (Check all applicable) X Director X X Officer (give title below) Chief Scientist	10% Owner Other (specify	helow) 6. Ir	idividual or Joint/Grou	Original Filed (Month/Day/Year) up Filing (Check Applicable Line) One Reporting Person More than One Reporting Person	
Table I - Non-Derivative Securities Beneficially Owned										
				2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock				20,689,892	D					
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)			ate	Security (Instr. 4) Conv		4. Conversion or Exercise Price of	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
		Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	(111301.3)			
Stock Option (Righ	nt to Buy)		(1)	01/31/2031	Common Stock	464,019	10	D		

Explanation of Responses:

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan (the "Plan")) through each vesting date, one thirty-sixth (1/36th) of the shares subject to the Option shall vest each month over the thirty-six (36) months following the Vesting Commencement Date (as defined below) on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 31, 2021.

Remarks:

/s/ Anna Mowry, as Attorney-in-Fact 06/09/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Nautilus Biotechnology, Inc. (the "Company"), hereby constitutes and appoints Sujal Patel

- 1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion deto
- 2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national assoc.

 The undersigned hereby ratifies and confirms all that said attorneys in-fact and agent shall do or cause to be done by virtue hereof. The undersigned of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 9th day of June, 2021.

Signature: /s/ Parag Mallick
Print Name: Parag Mallick